Who Owns Prime Medicine Stock?
NASDAQ: PRMEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 57.48%
- Held by insiders
- 17.01%
- Institutional holders
- 251
- Institutions 57.5%
- Insiders 17.0%
- Public and other 25.5%
Who owns Prime Medicine stock?
Institutional investors own about 57.5% of Prime Medicine's shares, spread across 251 institutions that file 13F reports. That level of institutional ownership is moderate. Insiders, including executives, directors and large founding shareholders, hold 17.01% of PRME.
The largest institutional holders are Arch Venture Management, Llc (10.16%), Alphabet Inc. (9.10%) and Blackrock Inc. (5.89%). Together, the top 10 institutions control 44.4% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their PRME positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of PRME
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Arch Venture Management, Llc | 18.49M | 10.16% | +100.0% |
| Alphabet Inc. | 16.56M | 9.10% | 0.0% |
| Blackrock Inc. | 10.72M | 5.89% | +11.6% |
| ARK Investment Management, LLC | 10.04M | 5.52% | +20.3% |
| State Street Corporation | 6.15M | 3.38% | -18.9% |
| Vanguard Capital Management LLC | 4.58M | 2.52% | +1.3% |
| T. Rowe Price Investment Management, Inc. | 4.56M | 2.50% | -13.0% |
| Balyasny Asset Management LP | 3.56M | 1.96% | -10.3% |
| Casdin Capital, LLC | 3.17M | 1.74% | 0.0% |
| Woodline Partners LP | 3.01M | 1.65% | +0.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of PRME
| Fund | Shares | % Held |
|---|---|---|
| ARK ETF Trust-ARK Genomic Revolution ETF | 8.01M | 4.40% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.62M | 1.99% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.12M | 1.72% |
| ARK Venture Fund | 2.94M | 1.61% |
| iShares Trust-iShares Russell 2000 ETF | 2.44M | 1.34% |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1.36M | 0.75% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.30M | 0.71% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.22M | 0.67% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.04M | 0.57% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 888.07K | 0.49% |
Frequently asked questions
Who is the largest shareholder of Prime Medicine?
Arch Venture Management, Llc is the largest institutional shareholder of PRME, owning 10.16% of shares outstanding (18.49M shares) as of its latest 13F filing.
What percentage of Prime Medicine is owned by institutions?
Institutions own about 57.5% of PRME shares and 69.3% of the public float.
How much of Prime Medicine do insiders own?
Insiders, such as officers and directors, own about 17.01% of PRME shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.